scholarly journals p27Kip1 in Stage III Colon Cancer: Implications for Outcome following Adjuvant Chemotherapy in Cancer and Leukemia Group B Protocol 89803

2009 ◽  
Vol 15 (6) ◽  
pp. 2116-2122 ◽  
Author(s):  
Monica M. Bertagnolli ◽  
Robert S. Warren ◽  
Donna Niedzwiecki ◽  
Elke Mueller ◽  
Carolyn C. Compton ◽  
...  
2009 ◽  
Vol 27 (11) ◽  
pp. 1814-1821 ◽  
Author(s):  
Monica M. Bertagnolli ◽  
Donna Niedzwiecki ◽  
Carolyn C. Compton ◽  
Hejin P. Hahn ◽  
Margaret Hall ◽  
...  

Purpose Colon cancers exhibiting DNA mismatch repair (MMR) defects demonstrate distinct clinical and pathologic features, including better prognosis and reduced response to fluorouracil (FU) –based chemotherapy. This prospective study investigated adjuvant chemotherapy containing FU and irinotecan in patients with MMR deficient (MMR-D) colon cancers. Patients and Methods Cancer and Leukemia Group B 89803 randomly assigned 1,264 patients with stage III colon cancer to postoperative weekly bolus FU/leucovorin (LV) or weekly bolus irinotecan, FU, and LV (IFL). The primary end point was overall survival; disease-free survival (DFS) was a secondary end point. Tumor expression of the MMR proteins, MLH1 and MSH2, was determined by immunohistochemistry (IHC). DNA microsatellite instability was also assessed using a panel of mono- and dinucleotide markers. Tumors with MMR defects were those demonstrating loss of MMR protein expression (MMR-D) and/or microsatellite instability high (MSI-H) genotype. Results Of 723 tumor cases examined by genotyping and IHC, 96 (13.3%) were MMR-D/MSI-H. Genotyping results were consistent with IHC in 702 cases (97.1%). IFL-treated patients with MMR-D/MSI-H tumors showed improved 5-year DFS as compared with those with mismatch repair intact tumors (0.76; 95% CI, 0.64 to 0.88 v 0.59; 95% CI, 0.53 to 0.64; P = .03). This relationship was not observed among patients treated with FU/LV. A trend toward longer DFS was observed in IFL-treated patients with MMR-D/MSI-H tumors as compared with those receiving FU/LV (0.57; 95% CI, 0.42 to 0.71 v 0.76; 95% CI, 0.64 to 0.88; P = .07; hazard ratio interaction between tumor status and treatment, 0.51; likelihood ratio P = .117). Conclusion Loss of tumor MMR function may predict improved outcome in patients treated with the IFL regimen as compared with those receiving FU/LV.


2019 ◽  
Vol 8 (12) ◽  
pp. 5590-5599
Author(s):  
Safiya Karim ◽  
Christopher M. Booth ◽  
Kelly Brennan ◽  
Yingwei Peng ◽  
D. Robert Siemens ◽  
...  

2016 ◽  
Vol 61 ◽  
pp. 1-10 ◽  
Author(s):  
F.N. van Erning ◽  
L.G.E.M. Razenberg ◽  
V.E.P.P. Lemmens ◽  
G.J. Creemers ◽  
J.F.M. Pruijt ◽  
...  

2006 ◽  
Vol 24 (22) ◽  
pp. 3535-3541 ◽  
Author(s):  
Jeffrey A. Meyerhardt ◽  
Denise Heseltine ◽  
Donna Niedzwiecki ◽  
Donna Hollis ◽  
Leonard B. Saltz ◽  
...  

Purpose Regular physical activity reduces the risk of developing colon cancer, however, its influence on patients with established disease is unknown. Patients and Methods We conducted a prospective observational study of 832 patients with stage III colon cancer enrolled in a randomized adjuvant chemotherapy trial. Patients reported on various recreational physical activities approximately 6 months after completion of therapy and were observed for recurrence or death. To minimize bias by occult recurrence, we excluded patients who experienced recurrence or died within 90 days of their physical activity assessment. Results Compared with patients engaged in less than three metabolic equivalent task (MET) -hours per week of physical activity, the adjusted hazard ratio for disease-free survival was 0.51 (95% CI, 0.26 to 0.97) for 18 to 26.9 MET-hours per week and 0.55 (95% CI, 0.33 to 0.91) for 27 or more MET-hours per week. The adjusted P for trend was .01. Postdiagnosis activity was associated with similar improvements in recurrence-free survival (P for trend = .03) and overall survival (P for trend = .01). The benefit associated with physical activity was not significantly modified by sex, body mass index, number of positive lymph nodes, age, baseline performance status, or chemotherapy received. Moreover, the benefit remained unchanged even after excluding participants who developed cancer recurrence or died within 6 months of activity assessment. Conclusion Beyond surgical resection and postoperative adjuvant chemotherapy for stage III colon cancer, for patients who survive and are recurrence free approximately 6 months after adjuvant chemotherapy, physical activity appears to reduce the risk of cancer recurrence and mortality.


2018 ◽  
Vol 14 ◽  
pp. 19-26
Author(s):  
Martin Hoffmann ◽  
Lucky Ogbonnaya ◽  
Claudia Benecke ◽  
Ruediger Braun ◽  
Markus Zimmermann ◽  
...  

2021 ◽  
Vol 4 (3) ◽  
pp. e213587
Author(s):  
Devon J. Boyne ◽  
Winson Y. Cheung ◽  
Robert J. Hilsden ◽  
Tolulope T. Sajobi ◽  
Atul Batra ◽  
...  

2017 ◽  
Vol 16 (3) ◽  
pp. e141-e145 ◽  
Author(s):  
Jo Tashiro ◽  
Shigeki Yamaguchi ◽  
Toshimasa Ishii ◽  
Hiroka Kondo ◽  
Kiyoka Hara ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document